Display Settings:


Send to:

Choose Destination
Ophthalmic Surg Lasers Imaging. 2012 Jul 19;43 Online:e73-9. doi: 10.3928/15428877-20120712-05.

Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion.

Author information

  • 1Department of Ophthalmology, Stanford University School of Medicine, California, USA.


Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is widely used for the treatment of macular edema associated with central retinal vein occlusion (CRVO). The authors present a series of three patients with CRVO who suffered apparent macular infarction within weeks of intravitreal administration of bevacizumab. Of the nearly 200 patients undergoing intravitreal injections of bevacizumab for this indication over a surveillance period of 3 years, this event occurred in three patients. This has not been described in the natural history of the disease and is associated with poor visual outcomes.

Copyright 2012, SLACK Incorporated.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for SLACK Incorporated.
    Loading ...
    Write to the Help Desk